Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)

Sever, Peter; Dahlöf, Björn; Poulter, Neil; Wedel, Hans; Beevers, Gareth; Caulfield, Mark; Collins, Rory; Kjeldsen, Sverre E.; Kristinsson, A; McInnes, Gordon T.; Mehlsen, Jesper; Nieminen, Markku S.; O’Brien, Eoin; Östergren, Jan; Investigators, Ascot

doi:10.2165/00003495-200464002-00005

Cited by 319 publications

(220 citation statements)

References 28 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…12,20,24 The present study extends the documented benefit of statins to people with moderate CKD, with estimated GFRs as low as 30 mL/min per 1.73 m 2 . We found that cardiovascular event rates increased in an apparently linear fashion with declining renal function, and the absolute benefit of treatment with pravastatin was greater among individuals with more severe CKD.…”

Section: Discussionsupporting

confidence: 65%

Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease

et al. 2004

View full text Add to dashboard Cite

Background-Limited data describe the cardiovascular benefit of HMG-CoA reductase inhibitors (statins) in people with moderate chronic kidney disease (CKD). The objective of this analysis was to determine whether pravastatin reduced the incidence of cardiovascular events in people with or at high risk for coronary disease and with concomitant moderate CKD. Methods and Results-We analyzed data from the Pravastatin Pooling Project (PPP), a subject-level database combining results from 3 randomized trials of pravastatin (40 mg daily) versus placebo. Of 19 700 subjects, 4491 (22.8%) had moderate CKD, defined by an estimated glomerular filtration rate of 30 to 59.99 mL/min per 1.73 m 2 body surface area. The primary outcome was time to myocardial infarction, coronary death, or percutaneous/surgical coronary revascularization. Moderate CKD was independently associated with an increased risk of the primary outcome (adjusted HR 1.26, 95% CI 1.07 to 1.49) compared with those with normal renal function. Among the 4491 subjects with moderate CKD, pravastatin significantly reduced the incidence of the primary outcome (HR 0.77, 95% CI 0.68 to 0.86), similar to the effect of pravastatin on the primary outcome in subjects with normal kidney function (HR 0.78, 95% CI 0.65 to 0.94). Pravastatin also appeared to reduce the total mortality rate in those with moderate CKD (adjusted HR 0.86, 95% CI 0.74 to 1.00, Pϭ0.045). Conclusions-Pravastatin reduces cardiovascular event rates in people with or at risk for coronary disease and concomitant moderate CKD, many of whom have serum creatinine levels within the normal range. Given the high risk associated with CKD, the absolute benefit that resulted from use of pravastatin was greater than in those with normal renal function.

show abstract

Section: Discussionsupporting

confidence: 65%

Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease

et al. 2004

View full text Add to dashboard Cite

show abstract

“…L'ultimo ATP, il terzo dall'istituzione del NCEP (ATP III), ha pubblicato il proprio rapporto nel maggio 2001 in forma d'Executive Summary [16] e nel dicembre 2002 [17] in forma completa. In seguito alla pubblicazione di cinque importanti trials clinici, i cui risultati hanno rilevanti implicazioni nella gestione dei pazienti dislipidemici, in particolare ad alto rischio [21][22][23][24][25], il panel di esperti dell'ATP III, con un articolo pubblicato nel 2004 [26] è stato in grado di ampliare sia gli scopi sia l'intensità del trattamento ipocolesterolemizzante in soggetti ad alto rischio.…”

Section: National Cholesterol Education Program's (Ncep's) Atp IIIunclassified

“…Studi pubblicati di recente indicano che questo trattamento può risultare efficace anche nei soggetti più anziani e nelle persone con livelli di colesterolo inferiori [22,24].…”

Section: Lipidi Plasmaticiunclassified

From risk charts to guidelines: tools for evaluation and management of cardiovascular risk

Castelló

Colivicchi²,

Sclavo

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

RASSEGNA IntroduzioneNonostante che i dati epidemiologici abbiano dimostrato come l'aumento dell'aspettativa di vita osservato negli ultimi decenni nei paesi occidentali sia in larga misura dovuto agli effetti favorevoli del vistoso miglioramento delle tecniche diagnostiche e dell'introduzione di efficaci strategie terapeutiche farmacologiche e strumentali per il trattamento delle malattie cardiovascolari, l'incidenza e la letalità di queste ultime continuano a rimanere elevate a causa sia dell'invecchiamento della popolazione generale, con la conseguente prolungata esposizione agli stress psico-fisici, sia delle sfavorevoli modificazioni dello stile di vita associate all'urbanizzazione ed all'industrializzazione. Pertanto il carico globale di malattia legato alle patologie cardiovascolari continua a crescere in modo drammatico con risvolti economici sempre meno sostenibili per i sistemi sanitari pubblici, a causa dei crescenti costi relativi alle tecnologie diagnostiche avanzate, alle ospedalizzazioni, alle terapie farmacologiche ed alle procedure strumentali, nonché della crescente domanda di salute da parte della popolazione.La prevenzione della comparsa e della progressione della malattia aterotrombotica costituisce nel contempo sia una risposta a questo scenario sia un problema aggiuntivo, in quanto comporta un ulteriore costo in sistemi con possibilità di consumo di risorse sempre minore. La moderna pratica della prevenzione cardiovascolare richiede pertanto che gli interventi (percorsi diagnostici e terapeutici) a livello sia di popolazione sia del singolo cittadino siano sempre più precisi, efficaci ed appropriati. In quest'ottica assume rilevanza preponderante la corretta stratificazione del rischio cardiovascolare, cui deve conseguire un'adeguata risposta terapeutica. A tale scopo sono stati messi a disposizione dei clinici interessati alla prevenzione diversi strumenti di lavoro, ed in particolare alcune carte del rischio e differenti linee guida, di grande importanza scientifica e culturale ma presentanti spesso notevoli complessità e difficoltà di trasferimento alla gestione clinica dei singoli pazienti. Despite the wide improvement of diagnostic techniques and the introduction of effective pharmacological and instrumental therapeutic strategies aimed to the treatment of cardiovascular diseases, their incidence and lethality are still elevated, with economic implications increasingly less sustainable by the public medical systems.The modern practice of cardiovascular prevention requires, thus, that diagnostic and therapeutic interventions, both at population level and on the single patient, should be more and more precise, effective, and appropriate. From this point of view, a correct global cardiovascular risk stratification assumes a preponderant relevance, in order to allow an adequate therapeutical response. For this purpose several work instruments, as risk charts and guidelines, namely dedicated to arterial hypertension and dyslipidemias, were developed and offered to clinicians interested in ...

show abstract

“…Estos modelos son probablemente la mejor manera de estudiar la fisiopatología y las complicaciones ejercidas por una dieta hipercalórica así como la alternativas de tratamientos con sustancias, demostrando efectos favorables en la disminución de peso, en el tejido adiposo y el control de las dislipidemias, teniendo como finalidad equilibrar la concentración del LDL, reducir la de triglicéridos y aumentar la del HDL, con inhibidores de la síntesis hepática del colesterol, como las estatinas o con fibratos, para reducir la síntesis de las lipoproteínas VLDL a través del el hígado, e incrementar la de las HDL 15,16 .…”

Section: N T R O D U C C I ó Nunclassified

Efecto de la administración subcrónica de glucosamina oral en la regulación del peso corporal, glucemia y dislipidemias provocada por una dieta hipercalórica en rata Wistar

Barrientos‐Alvarado

Vázquez²,

Oscoy³

et al. 2014

Rev. Nutr.

View full text Add to dashboard Cite

ObjetivoEste estudio evaluó el efecto de la glucosamina oral en el sobrepeso y dislipidemia provocada por una dieta hipercalórica en ratas. MétodosEn 4 grupos de ratas Wistar: alimentados con dieta comercial para roedores y agua de beber sin grupo de control y con glucosamina (500 mg/kg-1 por día) grupo glucosamina y con dieta hipercalórica enriquecida al 24% (g/g) compuesta por manteca de cerdo y agua de beber sin grupo hipercalórico y con glucosamina grupo hipercalórico + grupo glucosamina, durante 22 semanas, se evaluaron el peso corporal, grasa abdominal, niveles de glucemia, triglicéridos, colesterol total y lipoproteínas de alta densidad en suero. ResultadosSe observó un aumento del peso corporal y glucemia en suero con dislipidemias en el grupo con dieta hipercalórica grupo hipercalórico versus grupo de controle (p<0.001); al administrarse glucosamina para esta misma dieta grupo hipercalórico + grupo glucosamina se minimizaron los efectos presentados, disminuyendo la cantidad de grasa abdominal y los niveles del perfil lípido en suero (p>0.05) y regulándose el peso corporal, las lipoproteínas de alta densidad y la glucemia basal (p<0.05). ConclusionLa glucosamina reguló el peso corporal y la glucemia en sangre y minimizó las dislipidemias provocadas por la dieta hipercalórica, favoreciendo el aumento de colesterol lipoproteínas de alta densidad en las ratas. No afectó el peso corporal y el metabolismo lipídico cuando se administró con dieta comercial.Palabras ilave: Glucemia. Glucosamina. HDL-colesterol. Peso corporal. A B S T R A C T Objective This study evaluated the effect of oral glucosamine on overweight and dyslipidemia caused by a high-fat diet in rats. Methods Four groups of Wistar rats: fed with commercial rodent food and drinking water without (control group) and with glucosamine (500 mg kg-1 per day) and a high-fat diet enriched with 24% (g/g) butter pork and drinking water without and with glucosamine, for 22 weeks; the body weight, abdominal fat, blood glucose, triglycerides, total cholesterol, and high density lipoprotein in serum were evaluated. Results Body

show abstract

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)

Cited by 319 publications

References 28 publications

Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease

Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease

From risk charts to guidelines: tools for evaluation and management of cardiovascular risk

Efecto de la administración subcrónica de glucosamina oral en la regulación del peso corporal, glucemia y dislipidemias provocada por una dieta hipercalórica en rata Wistar

Contact Info

Product

Resources

About